Serveur d'exploration sur le lymphœdème

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Primary pelvic exenteration in cervical cancer patients.

Identifieur interne : 006972 ( Main/Curation ); précédent : 006971; suivant : 006973

Primary pelvic exenteration in cervical cancer patients.

Auteurs : Laszlo Ungar [Hongrie] ; Laszlo Palfalvi ; Zoltan Novak

Source :

RBID : pubmed:18775558

Descripteurs français

English descriptors

Abstract

Despite the reports of a number of leading institutions concerning the use of primary exenteration, there are differences in regard to definition, indications, and interpretation of results of this treatment approach to cervical cancer. In this paper we present our own experience with 41 cervical cancer patients treated with primary exenteration at St. Stephen Hospital Budapest. We explore some important unsettled aspects (definition, indications, and quality of life consequences) of this treatment modality in view of our own experience and the literature. Between January 1993 and June 2006, 2540 invasive cervical cancer patients were seen at the gynecologic oncology service of the St. Stephens Hospital Budapest. Two hundred twelve (8%) of these patients were surgically explored with the plan of an exenterative surgery. Exenteration was the primary treatment in 41 (25%) of 166 completed exenterations; these 41 cases included 2 cases of supralevator total exenteration, 9 cases of supralevator anterior exenteration, and 30 cases of partial supralevator anterior exenteration. In the 2 total exenteration patients, anal function was restored with a low rectal anastomosis, with a temporary defunctioning colostomy in 1 patient. Urethral function was restored in 9 out of 11 supralevator exenteration cases with the Budapest pouch bladder replacement technique. In the remaining 2 cases, a Bricker conduit was used for urinary diversion. There was no operation-related mortality in this cohort of patients. An external fecal or urinary stoma was avoided in 38 (93%) out of the 41 primary exenteration patients; in 1 patient a temporary defunctioning colostomy was used; and in 2 patients a permanent ileal conduit was created. In 9 patients (22%), complications (ileus and peritonitis, occlusion of the femoral artery, stricture of the implanted ureter, and postoperative ureterovaginal fistula) necessitated surgical intervention. A quality of life study revealed the need for prolonged self-catheterization, partial (mainly night time) incontinence, and lymphedema in 7 patients. We consider and suggest that an en bloc resection of part(s) of the urinary bladder and/or the rectum with the uterine cervix should be considered an exenteration (partial exenteration). A 50% survival rate of a select group of stage IVA cervical cancer patients treated with primary exenteration can be considered significant, but cannot be considered superior to that of chemoradiation therapy. The same applies when considering treatment-related mortality and complications that require operative interventions. Low rectal anastomosis and orthotopic bladder replacement with a relative low risk of fistula formation in non-irradiated patients constitute a strong quality of life argument in favor of primary exenteration in a select group of stage IVA cervical cancer patients.

DOI: 10.1016/j.ygyno.2008.07.041
PubMed: 18775558

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:18775558

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Primary pelvic exenteration in cervical cancer patients.</title>
<author>
<name sortKey="Ungar, Laszlo" sort="Ungar, Laszlo" uniqKey="Ungar L" first="Laszlo" last="Ungar">Laszlo Ungar</name>
<affiliation wicri:level="1">
<nlm:affiliation>Gynecologic Oncology Department, Hungarian National Cancer Institute, Hungary. ungarl@t-email.hu</nlm:affiliation>
<country xml:lang="fr">Hongrie</country>
<wicri:regionArea>Gynecologic Oncology Department, Hungarian National Cancer Institute</wicri:regionArea>
<wicri:noRegion>Hungarian National Cancer Institute</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Palfalvi, Laszlo" sort="Palfalvi, Laszlo" uniqKey="Palfalvi L" first="Laszlo" last="Palfalvi">Laszlo Palfalvi</name>
</author>
<author>
<name sortKey="Novak, Zoltan" sort="Novak, Zoltan" uniqKey="Novak Z" first="Zoltan" last="Novak">Zoltan Novak</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2008">2008</date>
<idno type="RBID">pubmed:18775558</idno>
<idno type="pmid">18775558</idno>
<idno type="doi">10.1016/j.ygyno.2008.07.041</idno>
<idno type="wicri:Area/PubMed/Corpus">003151</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003151</idno>
<idno type="wicri:Area/PubMed/Curation">003151</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003151</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003151</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003151</idno>
<idno type="wicri:Area/Ncbi/Merge">002F31</idno>
<idno type="wicri:Area/Ncbi/Curation">002F31</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002F31</idno>
<idno type="wicri:Area/Main/Merge">006A66</idno>
<idno type="wicri:Area/Main/Curation">006972</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Primary pelvic exenteration in cervical cancer patients.</title>
<author>
<name sortKey="Ungar, Laszlo" sort="Ungar, Laszlo" uniqKey="Ungar L" first="Laszlo" last="Ungar">Laszlo Ungar</name>
<affiliation wicri:level="1">
<nlm:affiliation>Gynecologic Oncology Department, Hungarian National Cancer Institute, Hungary. ungarl@t-email.hu</nlm:affiliation>
<country xml:lang="fr">Hongrie</country>
<wicri:regionArea>Gynecologic Oncology Department, Hungarian National Cancer Institute</wicri:regionArea>
<wicri:noRegion>Hungarian National Cancer Institute</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Palfalvi, Laszlo" sort="Palfalvi, Laszlo" uniqKey="Palfalvi L" first="Laszlo" last="Palfalvi">Laszlo Palfalvi</name>
</author>
<author>
<name sortKey="Novak, Zoltan" sort="Novak, Zoltan" uniqKey="Novak Z" first="Zoltan" last="Novak">Zoltan Novak</name>
</author>
</analytic>
<series>
<title level="j">Gynecologic oncology</title>
<idno type="eISSN">1095-6859</idno>
<imprint>
<date when="2008" type="published">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Cohort Studies</term>
<term>Female</term>
<term>Humans</term>
<term>Pelvic Exenteration (adverse effects)</term>
<term>Pelvic Exenteration (methods)</term>
<term>Quality of Life</term>
<term>Treatment Outcome</term>
<term>Uterine Cervical Neoplasms (surgery)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Exentération pelvienne ()</term>
<term>Exentération pelvienne (effets indésirables)</term>
<term>Femelle</term>
<term>Humains</term>
<term>Qualité de vie</term>
<term>Résultat thérapeutique</term>
<term>Tumeurs du col de l'utérus ()</term>
<term>Études de cohortes</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en">
<term>Pelvic Exenteration</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr">
<term>Exentération pelvienne</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en">
<term>Pelvic Exenteration</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en">
<term>Uterine Cervical Neoplasms</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Cohort Studies</term>
<term>Female</term>
<term>Humans</term>
<term>Quality of Life</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Exentération pelvienne</term>
<term>Femelle</term>
<term>Humains</term>
<term>Qualité de vie</term>
<term>Résultat thérapeutique</term>
<term>Tumeurs du col de l'utérus</term>
<term>Études de cohortes</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Despite the reports of a number of leading institutions concerning the use of primary exenteration, there are differences in regard to definition, indications, and interpretation of results of this treatment approach to cervical cancer. In this paper we present our own experience with 41 cervical cancer patients treated with primary exenteration at St. Stephen Hospital Budapest. We explore some important unsettled aspects (definition, indications, and quality of life consequences) of this treatment modality in view of our own experience and the literature. Between January 1993 and June 2006, 2540 invasive cervical cancer patients were seen at the gynecologic oncology service of the St. Stephens Hospital Budapest. Two hundred twelve (8%) of these patients were surgically explored with the plan of an exenterative surgery. Exenteration was the primary treatment in 41 (25%) of 166 completed exenterations; these 41 cases included 2 cases of supralevator total exenteration, 9 cases of supralevator anterior exenteration, and 30 cases of partial supralevator anterior exenteration. In the 2 total exenteration patients, anal function was restored with a low rectal anastomosis, with a temporary defunctioning colostomy in 1 patient. Urethral function was restored in 9 out of 11 supralevator exenteration cases with the Budapest pouch bladder replacement technique. In the remaining 2 cases, a Bricker conduit was used for urinary diversion. There was no operation-related mortality in this cohort of patients. An external fecal or urinary stoma was avoided in 38 (93%) out of the 41 primary exenteration patients; in 1 patient a temporary defunctioning colostomy was used; and in 2 patients a permanent ileal conduit was created. In 9 patients (22%), complications (ileus and peritonitis, occlusion of the femoral artery, stricture of the implanted ureter, and postoperative ureterovaginal fistula) necessitated surgical intervention. A quality of life study revealed the need for prolonged self-catheterization, partial (mainly night time) incontinence, and lymphedema in 7 patients. We consider and suggest that an en bloc resection of part(s) of the urinary bladder and/or the rectum with the uterine cervix should be considered an exenteration (partial exenteration). A 50% survival rate of a select group of stage IVA cervical cancer patients treated with primary exenteration can be considered significant, but cannot be considered superior to that of chemoradiation therapy. The same applies when considering treatment-related mortality and complications that require operative interventions. Low rectal anastomosis and orthotopic bladder replacement with a relative low risk of fistula formation in non-irradiated patients constitute a strong quality of life argument in favor of primary exenteration in a select group of stage IVA cervical cancer patients.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006972 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 006972 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Main
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:18775558
   |texte=   Primary pelvic exenteration in cervical cancer patients.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i   -Sk "pubmed:18775558" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1 

Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024